2022 Alliance for Nanotechnology in Cancer Principal Investigators’ Meeting
October 18 – October 19, 2022
The 2022 NCI Alliance for Nanotechnology in Cancer Annual Principal Investigator Meeting was held virtually on October 18–19, 2022. The meeting gathered the Alliance investigators and collaborators to present their recent research results as well as to discuss emerging opportunities in cancer nanotechnology. The scientific sessions included:
-
Cancer interventions enabled by new material designs;
-
Novel cancer therapies based on nanotechnology; and
-
Immunotherapies and vaccines.
The meeting also featured panel discussions on topics “What will be the next nano-drug approved by FDA?” and “Can nanotechnology aid in combating cancer metastasis?”
| Time | Session |
|---|---|
|
9–10 a.m. |
Join Meeting—Computer Check |
|
10–10:20 a.m. |
Welcome and Introduction Janet Eary, M.D., Associate Director, Cancer Imaging Program (CIP), DCTD, NCI |
|
10:20–11 a.m. |
Plenary Presentation Molly S Shoichet, Ph.D., University of Toronto |
|
Session I: Cancer Interventions Enabled By New Material Designs (Part 1) Moderator: Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI |
|
|
11–11:20 a.m. |
The Tumor Microenvironment In Nanoparticle Delivery and Function Zaver, Bhujwalla, Ph.D., Johns Hopkins University |
|
11:20–11:40 a.m. |
Imaging of Nanotherapeutic Drug Action Presented by Miles Miller, Ph.D., Massachusetts General Hospital |
|
11:40–Noon |
Copper-Depleting Nanotheranostics For Treating Triple Negative Breast Cancer Jianghong Rao, Ph.D., Stanford University |
|
Noon–12:20 p.m. |
In Situ Cancer Cell Specific Biomineralization To Overcome Nanoparticle Delivery Barriers and Sensitize Pancreatic Cancer To Radiotherapy Konstantin Sokolov, Ph.D., University of Texas MD Anderson Cancer Center |
|
12:20–12:40 p.m. |
Fluorescent Indocarbocyanine PEGylated Lipid Nanoparticles For Understanding And Overcoming Barriers To Drug Delivery In Invasive Glioblastoma Dmitri Simberg, Ph.D., University of Colorado Denver |
|
12:40–1 p.m. |
Lunch Break |
|
Session II: Discussion Panel: What Will Be The Next Nano-Drug Approved By FDA? Moderator: Andrew Wang, M.D., UT Southwestern Medical Center |
|
|
1:10–2:10 p.m. |
Panel:
|
|
Session III: Novel Cancer Therapies Based On Nanotechnology Moderator: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
|
|
2:10–2:30 p.m. |
Ultrasmall Particle-Based Solutions For Inducing Ferroptosis And Improving Antitumor Immune Responses In Cancer Michelle Bradbury, M.D., Ph.D., Memorial Sloan Kettering Cancer Center |
|
2:30–2:50 p.m. |
Development Of Multifunctional Drug And Immune Modulator Delivery Nanoparticles For The Treatment Of Cancer Patients With Comorbid Atherosclerosis Lily Yang, M.D., Ph.D., Emory University |
|
2:50–3:10 p.m. |
Nanodelivery Platform For Antibody Drugs Targeting NHL Masakazu Kamata, Ph.D., University of Alabama at Birmingham |
|
3:10–3:30 p.m. |
Towards Translation Of MU-CN29: New Therapeutic Nanoparticle For Drug Resistant NSCLC Raghuramann Kannan, M.D., University of Missouri-Columbia |
|
3:30–3:45 p.m. |
Break |
|
3:45–4:05 p.m. |
Targeted Therapeutics For Ovarian Cancer And Its Microenvironment—Treatment And Theoretical Modeling Gabriel Lopez-Berestein, M.D., University Of Texas MD Anderson Cancer Center |
|
4:05–4:25 p.m. |
TNBC Ligand-Displaying Exosomes Using RNA Nanotechnology For Targeted Cytosol Delivery Of Rnai Without Endosome Entrapment Presented by Daniel Binzel, Ph.D., Ohio State University (MPI) |
|
4:25–4:45 p.m. |
Novel Approach To Attenuate Small Cell Lung Cancer Growth And Metastasis Mohd Wasim Nasser, Ph.D., University of Nebraska Medical Center |
|
4:45–5 p.m. |
Q&A/Day 1 Wrap-Up Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
| Time | Session |
|---|---|
|
9–10 a.m. |
Join Meeting-Computer Check |
|
10–10:10 a.m. |
Day 1 Recap |
|
Session IV: Cancer Interventions Enabled By New Material Designs (Part 2) Moderator: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
|
|
10:10–10:30 a.m. |
Development Of A Novel Biodegradable Inorganic Nanoparticle Therapeutic For Cancer Jin Xie, Ph.D., University of Georgia |
|
10:30–10:50 a.m. |
The Development Of Novel Radiation-Sensitizer Based On Ultra-Small Carbon Dots Zibo Li , Ph.D., University of North Carolina, Chapel Hill |
|
10:50–11:10 a.m. |
Stimuli-Responsive Mucin1-Specific Nanoparticles For Efficacious Combinatorial Chemotherapy Of Pancreatic Ductal Adenocarcinoma Juan Luis Vivero-Escoto, Ph.D., University of North Carolina, Charlotte |
|
11:10–11:30 a.m. |
Nanotechnology For Targeted Therapy And Fundamental Understanding Of Xiaoming He, Ph.D., University of Maryland, College Park |
|
11:30–11:50 a.m. |
Map Leukemia-Immune Cell Talks With Nanoplasmon Ruler In CAR T-Cell Immunotherapy Presented by Pengyu Chen, Ph.D., Auburn University (MPI) |
|
11:50–12:20 p.m. |
Lunch Break |
|
Session V: Panel Discussion: Can Nanotechnology Aid In Combating Cancer Metastasis? Moderator: Patricia Steeg, Ph.D., Center For Cancer Research, NCI |
|
|
12:20–1:20 p.m. |
Panel:
|
|
Session VI: Immunotherapies And Vaccines Moderator: Leela Rani Avula, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
|
|
1:20–1:40 p.m. |
A Cobalt Porphyrin Nanoliposome Adjuvant For MHC-I-Restricted Cancer Peptide Vaccines Jonathan Lovell, Ph.D., State University of New York at Buffalo |
|
1:40–2 p.m. |
Innovative Research For Cancer Nanotechnology (IRCN) For Enhancing Melanoma-Specific Immune Responses By The Rational Design Of Spherical Nucleic Acids Presented by Bin Zhang, M.D., Ph.D., Northwestern University (MPI) |
|
2–2:20 p.m. |
Targeting Effector Immune Cells To Cancer With Chemically Self-Assembled Nanorings (CSANs) Carston Wagner, Ph.D., University Of Minnesota |
|
2:20–2:40 p.m. |
Break |
|
2:40–3 p.m. |
Toward Translation Of An Immunotherapeutic Nanomedicine For Neuroblastoma John Tanner Wilson, Ph.D., Vanderbilt University |
|
3–3:20 p.m. |
Whitlockite Nanoparticle-Based Immunotherapy For Bone Metastasis Presented by Hae Lin Jang, Ph.D., Brigham And Women's Hospital (MPI) |
|
3:20–3:40 p.m. |
Toward Translation Of A Plant Virus-Based In Situ Vaccination Nanotechnology Nicole Franziska Steinmetz, Ph.D., University Of California, San Diego |
|
3:40–4 p.m. |
Closing Remarks Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI |